12th Oct 2020 14:37
Yourgene Health PLC - Manchester-based molecular diagnostics group which develops and commercialises genetic products and services - Says its oncology product, Elucigene DPYD test, is now being used in Wales to routinely screen all cancer patients prior to the start of treatment with chemotherapeutic drug 5-Fluorouracil, to identify the risk of severe side effects. Elucigene DPYD is a genotyping test that can identify cancer patients with DPD deficiency, which can cause severe and sometimes lethal side effects in patients being treated with chemotherapeutic drug 5-Fluorouracil. Will be providing the Elucigene DPYD tests to screen for approximately 200 patients each month for the next year. If 2,400 patients are screened, and the positive rate of 6% continues, Yourgene anticipates that 144 cancer patients will be prevented from having toxic chemotherapy reactions.
Current stock price: 19.60 pence
Year-to-date change: up 48%
By Greg Roxburgh; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
YGEN.L